Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site

Ovarian Cancer


Na Li


Annals of Oncology (2019) 30 (suppl_5): v574-v584. 10.1093/annonc/mdz257


N. Li1, Y. Cheng2, L. Chen1, H. Zuo1, Y. Weng1, J. Zhou1, H. Liu1, M. Peng1, Q. Song1

Author affiliations

  • 1 Oncology, Renmin Hospital of Wuhan University, 430060 - Wuhan/CN
  • 2 Gynaecology, Renmin Hospital of Wuhan University, 430060 - Wuhan/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1993


Circulating tumor cell (CTC) detection methods based on epithelial cell adhesion molecule (EpCAM) have low detection rates in epithelial ovarian cancer (EOC). Meanwhile, folate receptor alpha (FRα) has high expression in EOC cells. We explored the feasibility of combining FRα and EpCAM as CTC capture targets in EOC.


EpCAM and FRα antibodies were linked to magnetic nanospheres (MNs) using the principle of carbodiimide chemistry. Blood samples from healthy donor spiked with A2780 ovarian cancer cells were used for detecting the capture rate. Ninety-five blood samples from 30 patients with EOC were used for comparing the positive rate of detection when using anti-EpCAM-MNs alone with that when using combination of anti-EpCAM-MNs and anti-FRα-MNs. Samples from 28 patients initially diagnosed with EOC and who did not undergo any treatment and 20 patients with ovarian benign disease were used for evaluating the sensitivity and specificity of combination of anti-EpCAM-MNs and anti-FRα-MNs.


Regression analysis between the number of recovered and that of spiked A2780 cells revealed yEpCAM = 0.535x (R2 = 0.99), yFRα = 0.901x (R2 = 0.99) and yEpCAM+FRα = 0.928x (R2 = 0.99). In mixtures of A2780 and MCF7 cells, the capture rate was 92% using the combination of anti-EpCAM-MNs and anti-FRα-MNs, exceeding the rate when using anti-EpCAM-MNs or anti-FRα-MNs alone by approximately 20% (P < 0.01). The combination of anti-EpCAM-MNs and anti-FRα-MNs showed significantly increased positive rate compared with anti-EpCAM-MNs alone (χ2 = 14.45, P < 0.001). Sensitivity values were 0.536 and 0.75 when using anti-EpCAM-MNs alone and when using the combination of anti-EpCAM-MNs and anti-FRα-MNs, respectively. Specificity values were 0.9 and 0.85, respectively. The combination of anti-EpCAM-MNs and anti-FRα-MNs improved the sensitivity of CTC detection in patients with newly diagnosed EOC (χ2 = 4.17; P = 0.041).


The combination of FRα and EpCAM is feasible as a CTC capture target of CTC detection in patients with EOC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


The NNSFC (National Natural Science Foundation of China) (81802980, 81770169, 81670144) and the Health Committee Research Project Fund of Hubei Province (WJ2019M179).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.